Stockscreener 앱 받기
17.03
1.79%
0.30
전일 마감가:
$16.73
열려 있는:
$16.72
하루 거래량:
398.11K
Relative Volume:
1.09
시가총액:
$6.03B
수익:
$4.89B
순이익/손실:
$-263.00M
주가수익비율:
-22.02
EPS:
-0.7734
순현금흐름:
$-167.84M
1주 성능:
+0.18%
1개월 성능:
-2.41%
6개월 성능:
+20.18%
1년 성능:
+2.34%
1일 변동 폭
$16.61
$17.22
1주일 범위
$16.60
$17.45
52주 변동 폭
$10.45
$17.86
Bausch Lomb Corp Stock (BLCO) Company Profile
명칭
Bausch Lomb Corp
전화
908-541-5456
주소
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
17.03 | 5.93B | 4.89B | -263.00M | -167.84M | -0.7734 |
|
ISRG
Intuitive Surgical Inc
|
485.84 | 169.97B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
175.89 | 50.58B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
79.20 | 38.58B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
44.55 | 37.11B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
252.55 | 35.80B | 5.40B | 1.49B | 1.78B | 10.12 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | 개시 | Goldman | Neutral |
| 2025-05-02 | 재확인 | H.C. Wainwright | Buy |
| 2025-03-28 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-07-10 | 개시 | Raymond James | Outperform |
| 2024-05-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-12-12 | 개시 | Stifel | Hold |
| 2023-10-03 | 재개 | Evercore ISI | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-03-09 | 개시 | Needham | Hold |
| 2022-12-21 | 개시 | Barclays | Equal Weight |
| 2022-09-12 | 개시 | H.C. Wainwright | Buy |
| 2022-07-26 | 개시 | RBC Capital Mkts | Outperform |
| 2022-06-24 | 개시 | Evercore ISI | Outperform |
| 2022-06-06 | 개시 | Citigroup | Buy |
| 2022-05-31 | 개시 | Deutsche Bank | Hold |
| 2022-05-31 | 개시 | Goldman | Neutral |
| 2022-05-31 | 개시 | Guggenheim | Buy |
| 2022-05-31 | 개시 | JP Morgan | Neutral |
| 2022-05-31 | 개시 | Jefferies | Buy |
| 2022-05-31 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 개시 | Wells Fargo | Overweight |
| 2022-05-11 | 개시 | Cowen | Outperform |
모두보기
Bausch Lomb Corp 주식(BLCO)의 최신 뉴스
Should Bausch + Lomb’s Mandatory AI Training Strategy Reshape the BLCO Execution Story? - Yahoo Finance
Assessing Bausch + Lomb (BLCO) Valuation As Shorter Term Shareholder Returns Improve - Yahoo Finance
Aug PreEarnings: Will Bausch Lomb Corporation outperform its industry peersQuarterly Trade Review & Weekly Stock Performance Updates - baoquankhu1.vn
The Truth About Bausch + Lomb Corp: Is This Eye-Care Giant Quietly Winning While No One’s Looking? - AD HOC NEWS
Bausch + Lomb CEO: Standing still is the new falling behind - Fortune
Nicox : Présentation des données des études de Phase 3 de NCX 470 au congrès annuel 2026 de l’American Glaucoma Society (AGS) - GlobeNewswire Inc.
3 Reasons to Sell BLCO and 1 Stock to Buy Instead - Finviz
Bausch + Lomb (NYSE:BLCO) Seems To Be Using A Lot Of Debt - 富途牛牛
Bausch + Lomb (NYSE:BLCO) Shares Down 0.9%What's Next? - MarketBeat
Published on: 2026-02-02 10:13:14 - baoquankhu1.vn
Bausch + Lomb Likely to Report a Q4 Beat on FX Tailwinds, Robust Performance of Eye Disease Portfolio, RBC Says - marketscreener.com
RBC Capital Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Raises Target Price to $21 - 富途牛牛
Bausch & Lomb stock price target raised to $21 from $19 at RBC Capital - Investing.com Nigeria
Bausch & Lomb stock price target raised to $21 from $19 at RBC Capital By Investing.com - Investing.com South Africa
Bausch Health stock unchanged as Phase 3 RED-C trial fails primary endpoint - Investing.com India
Bausch + Lomb Corp: Eyes On The Numbers As BLCO Tests Investor Patience - AD HOC NEWS
Growth Value: Is MLPR attractive for institutional investorsQuarterly Earnings Report & Proven Capital Preservation Tips - baoquankhu1.vn
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18 - BioSpace
Press Release: Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18 - 富途资讯
Stifel reiterates Hold rating on Bausch & Lomb stock amid competition concerns By Investing.com - Investing.com Nigeria
Stifel reiterates Hold rating on Bausch & Lomb stock amid competition concerns - Investing.com Nigeria
Bausch + Lomb Corporation (NYSE:BLCO) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Bausch + Lomb Corporation (BLCO) Stock Analysis: Navigating Growth in the Healthcare Sector - DirectorsTalk Interviews
Goldman Sachs Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $19 - 富途牛牛
Intraocular Lens Market Size to Reach USD 9.85 Billion by 2033, Growing at a CAGR of 6.48% - GlobeNewswire Inc.
Published on: 2026-01-09 11:41:10 - Улправда
Will Bausch + Lomb Corporation (S2L) stock benefit from Fed rate cutsProduct Launch & Safe Entry Momentum Tips - ulpravda.ru
Bausch + Lomb (NYSE:BLCO) Rating Lowered to "Hold" at Evercore ISI - MarketBeat
Bausch + Lomb (NYSE:BLCO) Valuation Check After Mixed 90 Day And 1 Year Shareholder Returns - Yahoo Finance
Evercore Downgrades Bausch + Lomb Corp.(BLCO.US) to Hold Rating, Cuts Target Price to $18 - 富途牛牛
Bausch + Lomb Corporation (BLCO): Investor Outlook on Growth Potential and Strategic Positioning - DirectorsTalk Interviews
Glaucoma stories and research drive new Bausch + Lomb awareness push - Stock Titan
Bausch & Lomb CorpEnters fourth amendment to credit agreement dated as of May 10, 2022SEC filing - marketscreener.com
Bausch + Lomb just refinanced $2.8B in debt to cut interest margin - Stock Titan
Bausch + Lomb Signs Fourth Amendment to Credit Agreement With JPMorgan Chase and Lenders - TradingView — Track All Markets
Bausch + Lomb refinances term loans, extends maturities - TipRanks
Bausch + Lomb (BLCO): Investor Outlook on a Visionary Healthcare Player with a Focused Growth Trajectory - DirectorsTalk Interviews
Does Bausch + Lomb’s Rising Focus on Eye Health Make Its Current Share Price Attractive? - simplywall.st
Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Top eye-care leaders to speak at J.P. Morgan's big healthcare event - Stock Titan
[8-K/A] Bausch & Lomb Corp Amends Material Event Report | BLCO SEC FilingForm 8-K/A - Stock Titan
Bausch + Lomb Makes Key Appointments to Board of Directors - VisionMonday.com
Bausch + Lomb Corporation (NYSE:BLCO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Will Bausch + Lomb Corporation stock keep outperforming rivalsMarket Trend Summary & Reliable Breakout Forecasts - Улправда
Published on: 2025-12-18 17:17:15 - Улправда
Icahn Money Manager Sues His Bosses and Bausch + Lomb Over Anti-White Bias - Insurance Journal
Fund Exits $6.6 Million Bausch + Lomb Stake as Shares Lag by 9% This Past Year - The Globe and Mail
Bausch + Lomb Announces Refinancing of Outstanding Term B Loans - VisionMonday.com
Bausch + Lomb appoints two new directors to board effective January - Investing.com
Bausch Lomb Corp (BLCO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.53%
1.58%
자본화:
|
볼륨(24시간):